Zydus Lifesciences’ shares ticked up in early trade on August 14 after the USFDA concluded a pre-approval inspection at its Ahmedabad facility with zero observations, reinforcing market confidence in the company’s compliance standards.
Zydus Lifesciences Ltd. opened marginally higher on the BSE on August 14, with the stock trading at ₹995.50, up 0.65% from the previous close, following a regulatory update that its SEZ–II manufacturing unit in Ahmedabad cleared a US Food and Drug Administration (USFDA) audit without any observations. The clean inspection outcome bolstered investor sentiment, highlighting operational and compliance strength.
The inspection, conducted from August 11–13, reviewed three products under the pre-approval process and assessed adherence to current Good Manufacturing Practices (cGMP). The company also confirmed that a separate USFDA surveillance inspection at its Baddi facility in Himachal Pradesh between August 4–13 resulted in four observations, none linked to data integrity issues.
From a financial standpoint, Zydus Lifesciences reported a 3.3% year-on-year growth in net profit to ₹1,466.8 crore for the recent quarter, with revenue up 5.9% to ₹6,573.7 crore. Over the past few months, the company has strengthened its global product portfolio, securing USFDA approvals for Diltiazem Hydrochloride Tablets USP and Celecoxib Capsules, along with a Notice of Compliance from Health Canada for ZDS–Varenicline tablets.
Also Read: Indian Stocks in Focus: Earnings, Deals, and Bulk Trades on August 14
The pharmaceutical major also expanded its overseas footprint with the acquisition of an 85.6% stake in Amplitude Surgical in July 2025, enhancing its presence in the orthopedic implants market.
In the last 12 months, Zydus Lifesciences’ stock has declined more than 15%, trading 18.31% below its 52-week high of ₹1,218.60 and 24.9% above its 52-week low of ₹797.05. The company’s current market capitalization stands at ₹1,00,170.59 crore.
READ MORE ON